New drug combo aims to reboot immune attack in resistant cancers
NCT ID NCT07219576
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times
Summary
This early-phase trial tests a combination of two drugs—retifanlimab (an immunotherapy) and ruxolitinib (a targeted pill)—in people with advanced lung or kidney cancer whose disease worsened after standard immunotherapy. The main goal is to find the safest dose of ruxolitinib when given with retifanlimab, and to see if the combo can shrink tumors. About 40 participants will take ruxolitinib twice daily at home and receive retifanlimab infusions every 4 weeks at the clinic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.